TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19020157

Group type: COMPARATOR
Intervention: Tapentadol HCl 50 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tapentadol HCl 75 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tapentadol HCl 100 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tapentadol HCl 200 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Morphine sulfate 60 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All doses of tapentadol HCl
Number of subjects: 400
Study: 16635169

Group type: EXPERIMENTAL
Intervention: 30% glucose solution
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 25
Study: 14668074

Group type: EXPERIMENTAL
Intervention: Home Smoking Control Index (policy in effect)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Predictors of policy at 6 and 12 months
Number of subjects: 325
Study: 10945011

Group type: COMPARATOR
Intervention: BH-AC-DM (daunorubicin, behenoyl cytarabine, 6-mercaptopurine)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: BH-AC-EDM (daunorubicin, behenoyl cytarabine, 6-mercaptopurine, etoposide)
Number of subjects: 655

Group type: COMPARATOR
Intervention: BH-AC-DM
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: BH-AC-EDM
Number of subjects: 655
Study: 8781610

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporine (CsA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard formulation of cyclosporine (CsA)
Number of subjects: 6
Study: 1740900

Group type: EXPERIMENTAL
Intervention: 10% Lipovenös
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20% Lipovenös
Number of subjects: 40
Study: 6399891

Group type: EXPERIMENTAL
Intervention: Dimetophrine 400 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31270544

Group type: EXPERIMENTAL
Intervention: Late mid-sleep corrected for sleep debt (MSFsc)
Number of subjects: 2936

Group type: EXPERIMENTAL
Intervention: Late sleep-onset time
Number of subjects: 2936

Group type: EXPERIMENTAL
Intervention: Indication of Delayed Sleep Phase Syndrome (DSPS)
Number of subjects: 2936

Group type: EXPERIMENTAL
Intervention: Moderately late chronotype in adulthood
Number of subjects: 2936

Group type: COMPARATOR
Intervention: Extremely early chronotype
Number of subjects: 2936
Study: 29117442

Group type: EXPERIMENTAL
Intervention: Hip flexion training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Knee extension training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 27175451

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 37
Study: 25543423

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 33

Group type: COMPARATOR
Intervention: Kuntai capsule
Number of subjects: 33
Study: 22273648

Group type: EXPERIMENTAL
Intervention: Monopolar microdissection needle
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Cold dissection
Number of subjects: 1419
Study: 20427729

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) fortified orange juice (1000 IU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin D(2) fortified orange juice (1000 IU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin D supplements (1000 IU of either D(2) or D(3))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (orange juice or capsule)
Number of subjects: 60
Study: 18669811

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 77
Study: 16248239

Group type: EXPERIMENTAL
Intervention: Modified huanglian wendan decoction (MHWD) plus Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Number of subjects: 90

Group type: COMPARATOR
Intervention: Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Number of subjects: 90
Study: 14708444

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined therapy (ACE inhibitors and verapamil)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no antihypertensive therapy)
Number of subjects: 75
Study: 10365612

Group type: EXPERIMENTAL
Intervention: Midazolam-ketamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol-fentanyl
Number of subjects: 60
Study: 8145430

Group type: EXPERIMENTAL
Intervention: Nifedipine (corinfar), 15‐80 mg daily for 12 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (triampur), 25‐100 mg daily for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 27758064

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise (25% peak oxygen uptake)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (65% peak oxygen uptake)
Number of subjects: 10
Study: 25560678

Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (OO)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion (SO)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (OO and SO)
Number of subjects: 103
Study: 26434885

Group type: EXPERIMENTAL
Intervention: Intravenous gemcitabine/cisplatin regimen plus daily oral metformin 500 mg (arm A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous gemcitabine/cisplatin regimen alone (arm B)
Number of subjects: 30
Study: 22209967

Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (calorie-restricted diet with or without resistance training)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk factors
Number of subjects: 132
Study: 21813010

Group type: EXPERIMENTAL
Intervention: ADAPT robotic task‐practice system
Number of subjects: 5
Study: 18998173

Group type: EXPERIMENTAL
Intervention: QuiXfil (Xeno III)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tetric Ceram (Syntac Classic)
Number of subjects: 43
Study: 16428533

Group type: EXPERIMENTAL
Intervention: ProSeal LMA (PLMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (CLMA)
Number of subjects: 30
Study: 14574513

Group type: EXPERIMENTAL
Intervention: AC PET imaging
Number of subjects: 23

Group type: COMPARATOR
Intervention: FDG PET imaging
Number of subjects: 23

Group type: COMPARATOR
Intervention: MIBI SPET imaging
Number of subjects: 23
Study: 11710962

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 10432881

Group type: EXPERIMENTAL
Intervention: Negative for malignancy FNAB
Number of subjects: 1181
Study: 7851306

Group type: EXPERIMENTAL
Intervention: Manually expressed breast milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pump expressed breast milk
Number of subjects: 30
Study: 2790538

Group type: EXPERIMENTAL
Intervention: Bolus Injection (BI) of recombinant interleukin-2 (IL-2) at a maximum tolerated dose of 3 X 10(6) U/m2 per day for 7 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous Infusion (CI) of recombinant interleukin-2 (IL-2) at a maximum tolerated dose of 10(6) U/m2 per day for 7 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both BI and CI
Number of subjects: 25
Study: 768911

Group type: EXPERIMENTAL
Intervention: Acebutolol (mean dosage 10 mg/kg, maximum 22 mg/kg)
Number of subjects: 50
Study: 31883082

Group type: EXPERIMENTAL
Intervention: Blonanserin transdermal patches (40-80 mg/day for 52 weeks)
Number of subjects: 223
Study: 30641337

Group type: EXPERIMENTAL
Intervention: ICAST-CH (ISPCAN Child Abuse Screening Tool – Child, Home Version)
Number of subjects: 6957
Study: 29214923

Group type: EXPERIMENTAL
Intervention: Creatine (Cr)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 43
Study: 25046241

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste with enzymatic action (papain and bromelain)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste with abrasive action (perlite/calcium carbonate)
Number of subjects: 90
Study: 23320780

Group type: EXPERIMENTAL
Intervention: Cemented bipolar implant (n=133)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Cemented unipolar head (n=128)
Number of subjects: 261
Study: 22099239

Group type: EXPERIMENTAL
Intervention: Intervention schools (classroom sessions to improve sun protection knowledge and attitudes towards hat use)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Intervention schools (for subgroup of 439 students)
Number of subjects: 439
Study: 17964826

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no LMWH treatment)
Number of subjects: 26
Study: 16806420

Group type: EXPERIMENTAL
Intervention: Prilocaine infiltration
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intramuscular diclofenac
Number of subjects: 114
Study: 12928047

Group type: EXPERIMENTAL
Intervention: Combination of serum markers including interleukin‐6 (IL‐6) receptor, protein alpha1 fraction, cysteine, and cholesterol concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single serum markers
Number of subjects: 0
Study: 11192361

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/Zok
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study: 9087161

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide nasal aerosol (220 micrograms, once daily for 6 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo nasal aerosol (once daily for 6 weeks)
Number of subjects: 56
Study: 8334542

Group type: EXPERIMENTAL
Intervention: 10 micrograms fenoterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 micrograms fenoterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 12
Study: 2868173

Group type: EXPERIMENTAL
Intervention: Antibiotic regimens for preventing or treating wound sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASEPSIS scoring method
Number of subjects: 0
Study: 29762063

Group type: EXPERIMENTAL
Intervention: Human-controlled avatar
Number of subjects: 78

Group type: COMPARATOR
Intervention: Computer-controlled agent
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 78
Study: 27723444

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 181
Study: 25314051

Group type: EXPERIMENTAL
Intervention: IHC4 score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammostrat score
Number of subjects: 0
Study: 22982184

Group type: EXPERIMENTAL
Intervention: Teduglutide (0.05 mg/kg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 20484101

Group type: EXPERIMENTAL
Intervention: Nitinol stent implantation
Number of subjects: 206

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 206
Study: 18820310

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lignocaine injection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 200
Study: 15198997

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 480
Study: 12509195

Group type: EXPERIMENTAL
Intervention: Color-form correspondence instruction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aesthetic-correspondence instruction
Number of subjects: 200
Study: 10703128

Group type: EXPERIMENTAL
Intervention: Surodex (intraocular dexamethasone drug delivery system)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo drug delivery system
Number of subjects: 150

Group type: COMPARATOR
Intervention: Topical dexamethasone (eye drop therapy)
Number of subjects: 150
Study: 8765813

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1913699

Group type: EXPERIMENTAL
Intervention: MK-458 (HPMC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 6789733

Group type: EXPERIMENTAL
Intervention: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 3 months
Number of subjects: 1033

Group type: COMPARATOR
Intervention: 12-month control regimen
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Selective chemotherapy (treatment started only after active disease confirmation)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: All initial cultures negative (short-course regimens)
Number of subjects: 1033
Study: 31075954

Group type: EXPERIMENTAL
Intervention: Phytochemicals (e.g., agaricus, curcumin, Neovastat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytochemicals
Number of subjects: 0
Study: 27824257

Group type: EXPERIMENTAL
Intervention: Perceived availability of offline social support
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Perceived family cohesion
Number of subjects: 237
Study: 26094974

Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg once daily
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 25604111

Group type: EXPERIMENTAL
Intervention: Slight sedation (Richmond Agitation Sedation Score -1 to 0, n = 38)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual sedation (Richmond Agitation Sedation Score -3 to -2, n = 40)
Number of subjects: 78
Study: 21890828

Group type: EXPERIMENTAL
Intervention: Teen Online Problem-Solving (TOPS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Internet resource comparison
Number of subjects: 41
Study: 19805790

Group type: EXPERIMENTAL
Intervention: Intention
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Perceived benefits and subjective norms
Number of subjects: 1463
Study: 17949807

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D
Number of subjects: 214

Group type: COMPARATOR
Intervention: Engerix-B (hepatitis B vaccine)
Number of subjects: 214
Study: 15331972

Group type: EXPERIMENTAL
Intervention: Temporal lobe surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontal lobe surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemispherotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corpus callosotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple subpial transection
Number of subjects: 0
Study: 11318982

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 1138
Study: 9152566

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Astemizole 10 mg once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8432221

Group type: EXPERIMENTAL
Intervention: Low Protein Diet (LPD) at 0.6 g.kg‐1.day‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Protein Diet (UPD)
Number of subjects: 30
Study: 3321657

Group type: EXPERIMENTAL
Intervention: Heparin-DHE
Number of subjects: 147290
Study: 30541015

Group type: EXPERIMENTAL
Intervention: Exclusive enteral nutrition (EEN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Corticosteroids (CS)
Number of subjects: 19
Study: 29353543

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (educational material)
Number of subjects: 66
Study: 25775225

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - standard single session
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - intensive 9-session model
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard outpatient group treatment (both MI groups)
Number of subjects: 217
Study: 23982800

Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 I.U.
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,000 I.U.
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,000 I.U. (overweight participants)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 I.U. and 1,000 I.U.
Number of subjects: 305
Study: 22526742

Group type: EXPERIMENTAL
Intervention: Surgical coniotomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quicktrach II (cuffed device)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Portex-Crico-Kit (cuffed device)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TracheoQuick (non-cuffed device)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Airfree (non-cuffed device)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quicktrach I (non-cuffed device)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous cannula (non-cuffed device)
Number of subjects: 20
Study: 20067607

Group type: EXPERIMENTAL
Intervention: Diclofenac (maximum daily dose of 150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (maximum daily dose of 3000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac and Acetaminophen (both groups)
Number of subjects: 0
Study: 17851566

Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype‐adjusted algorithms
Number of subjects: 191

Group type: COMPARATOR
Intervention: Warfarin by a validated algorithm
Number of subjects: 191
Study: 15982192

Group type: EXPERIMENTAL
Intervention: Symptom/Nebulizer Education Intervention (SNEI)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard Asthma Education (SAE)
Number of subjects: 221
Study: 12794711

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Double therapy with reverse transcriptase inhibitors
Number of subjects: 43
Study: 10575565

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b combined with ribavirin (1000 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Interferon alpha‐2b alone
Number of subjects: 52
Study: 8934367

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40-50% maximal oxygen uptake)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (70-80% maximal oxygen uptake)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 18
Study: 1884563

Group type: EXPERIMENTAL
Intervention: Immediate adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation without adjuvant treatment (Control)
Number of subjects: 0
Study: 6355230

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 24
Study: 30273549

Group type: EXPERIMENTAL
Intervention: Structured ADL retraining during PTA plus TAU
Number of subjects: 104

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 104
Study: 28369875

Group type: EXPERIMENTAL
Intervention: Lactoferrin with vitamin E and zinc (n = 82)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (n = 82)
Number of subjects: 168
Study: 26822579

Group type: EXPERIMENTAL
Intervention: Vorvida Internet-based self-help program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual/waitlist (CAU/WL) control group
Number of subjects: 0
Study: 25173668

Group type: EXPERIMENTAL
Intervention: Accurate, full-body photo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photo modified to make them appear thinner than usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photo modified to make them appear heavier than usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: No photo of themselves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait body checking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body parts checking
Number of subjects: 0
Study: 21985609

Group type: COMPARATOR
Intervention: Zolpidem alone (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem after pretreatment with fluvoxamine (5 mg zolpidem + 100 mg fluvoxamine)
Number of subjects: 0
Study: 20807867

Group type: EXPERIMENTAL
Intervention: Topical arnica cream
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 53
Study: 17145204

Group type: EXPERIMENTAL
Intervention: OPANA ER (oxymorphone extended release)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 16137356

Group type: EXPERIMENTAL
Intervention: Right atrium lactate concentration ([Lac]ra)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulmonary artery lactate concentration ([Lac]pa)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Right atrium oxygen saturation (SraO2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulmonary artery oxygen saturation (SpaO2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Delta[Lac] (change in lactate concentration)
Number of subjects: 45
Study: 15267190

Group type: EXPERIMENTAL
Intervention: ROM (rifampicin 600 mg + ofloxacin 400 mg + minocycline 100 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard WHO/MDT-PB six months' regimen
Number of subjects: 32
Study: 10586091

Group type: EXPERIMENTAL
Intervention: IL-2 in association with antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-2/ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 0